Shareholders
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
ShareholdersAs of Mar. 31, 2021
Dividend
| Classification | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
| Face value (KRW) | 500 | 500 | 500 |
| (Consolidated) Net profit (KRW in millions) | 350,241 | 350,241 | 350,241 |
| Total cash dividends (KRW in millions) | 350,241 | 350,241 | 350,241 |
| Dividend propensity (%) | 74.2 | 74.2 | 74.2 |
| Cash dividend per share (KRW) | 3,600 | 3,600 | 3,600 |
| Cash dividend propensity (%) | 4.6 | 4.6 | 4.6 |